FDA Approves Bayer's KERENDIA for Chronic Kidney Disease in Type 1 Diabetes

Key Facts

1The U.S. FDA approved KERENDIA to reduce the risk of chronic kidney disease progression in adults with type 1 diabetes.

In a move reflecting the expansion of therapeutic solutions for chronic conditions, the U.S. Food and Drug Administration (FDA) has approved Bayer's KERENDIA to reduce the risk of chronic kidney disease progression in adults with type 1 diabetes. The approval followed a Priority Review and was based on the drug's efficacy in reducing the urinary albumin-to-creatinine ratio, which slows the decline of kidney function. This regulatory milestone addresses a significant unmet need for patients who have had limited treatment options for decades.

Per market data, BAYRY shares closed at $14.05 on September 16, 2026, with the stock trading between a day low of $13.99 and a high of $14.19 during that session. This regulatory success strengthens Bayer's pharmaceutical portfolio by targeting a large patient population suffering from diabetes-related kidney complications, supporting a bullish outlook for the company's clinical expansion.

Traders should watch for price stability around the $14.05 level (close September 16, 2026) as the market digests the impact of this supplemental approval. While the upcoming economic calendar shows no direct catalysts for the healthcare sector in the immediate seven-day window, the focus will remain on Bayer's commercial execution following this FDA milestone.